Financial Performance & Outlook - The company increased its 2025 enterprise outlook to mid- to high single-digit growth in Adjusted EBITDA, excluding catastrophes[12,14] - The company is approaching 10% growth in Adjusted EPS, excluding catastrophes[12,14] - The company generated $298 million in cash[12] - The company returned $209 million to shareholders[12] - The company expects share repurchases of $250-$300 million[65] Global Housing - Global Housing Adjusted EBITDA, excluding catastrophes, increased by 25% in the first half of 2025, reaching $513 million[29] - Global Housing Adjusted EBITDA, excluding catastrophes, increased 18% in Q2 2025, reaching $244 million[57] - Global Housing's combined ratio, excluding prior year development, was 87% in the first half of 2025[31] Global Lifestyle - Global Lifestyle Adjusted EBITDA increased 6% in Q2 2025, or 7% on a constant currency basis[55,58] - Connected Living Adjusted EBITDA increased 9% in Q2 2025, or 11% on a constant currency basis[55,58]

eVTOL Design & Development - Eve-100 eVTOL design refinements enhance passenger experience, improve operational efficiency and safety[2,4] - The full-scale prototype is getting ready for its first flight, featuring a new 4-blade rotor configuration and folding mechanism[19,20,24] - Key achievements include successful pusher motor tests and installation, continuous lifter testing, and Beta Technologies as a new electric motor partner[22] Commercial Agreements & Pre-orders - Revo signed the first binding eVTOL order for $250 million, targeting entry into service in 2027 with 10 vehicles (binding) and 40 vehicles (options)[8,9,10] - Future Flight Global signed a Letter of Intent (LOI) for up to 54 eVTOLs serving Brazil and the United States[13] - Aerosolutions and Bluenest by Globalvia signed an LOI for up to 50 eVTOLs and TechCare services[13] - Eve has secured pre-orders for approximately 2,800 eVTOLs from 28 customers in 9 countries[14] - The pre-order book value is approximately $14 billion based on the current list price[15] Financial Performance - Research & Development (R&D) expenses for 2Q25 were $45.7 million, compared to $36.3 million in 2Q24[41] - Net loss for 2Q25 was $64.7 million, compared to a net loss of $36.4 million in 2Q24[41] - Free Cash Flow for 2Q25 was $(56.9) million, compared to $(31.4) million in 2Q24[41] - The company anticipates total cash consumption between US$200-250 million for 2025[44]

Financial Performance - Net revenue increased by 9.3% on a constant-currency basis and 10.3% organically in 2Q25[14] - Cardiopulmonary revenue grew by 12.7% in 2Q25, driven by strong consumables demand and Essenz Perfusion System sales[11, 24] - Neuromodulation revenue increased by 5.6% in 2Q25, with growth across all regions[11, 28] - Adjusted diluted EPS was $1.05 in 2Q25, favorably impacted by higher revenue and optimization of DTD program spend[11] - Adjusted free cash flow was $48 million in 2Q25, driven by stronger operating results and disciplined working capital management[11] - The company is raising the full-year 2025 revenue guidance by 200 basis points to 8.0% - 9.0% on a constant-currency basis and 9.0% - 10.0% on an organic basis[10] - The company is raising the full-year 2025 adjusted diluted earnings per share range to $3.70 - $3.80[10] - The company is raising the full-year 2025 adjusted free cash flow range to $140 million - $160 million[10] Clinical and Regulatory Milestones - Long-term, real-world evidence demonstrates efficacy of VNS Therapy in a wide range of seizure types in people with drug-resistant epilepsy[10] - Initiated process with CMS for reconsideration of national coverage for VNS Therapy for treatment-resistant depression[10, 11]

Financial Performance - BeOne reported Q2 2025 revenue of $1.3 billion, a 42% year-over-year increase[13] - BRUKINSA U S revenue reached $684 million, representing a 43% year-over-year growth[16] - TEVIMBRA revenue increased by 22% year-over-year[45] - GAAP earnings per ADS were $0.84, while non-GAAP earnings per ADS were $2.25[13] - GAAP operating cash flow was $264 million, and free cash flow was $220 million[13] BRUKINSA Highlights - BRUKINSA is the U S revenue leader among BTK inhibitors and the fastest-growing brand[15] - BRUKINSA demonstrated an overall response rate (ORR) ranging from 76.3% to 88.4% across different follow-up periods in the ALPINE trial[23] - In the ALPINE trial, BRUKINSA showed progression-free survival (PFS) superiority over ibrutinib in relapsed/refractory CLL patients, with a hazard ratio of 0.66 (95% CI: 0.52, 0.84)[26] Pipeline Development - Registrational filings for Sonro in China for R/R CLL and R/R MCL have been submitted[13] - Phase 3 trials have been initiated for Sonro in combination with CD20 antibody[13] - Global registrational filings for Sonro in R/R MCL are expected in the second half of 2025[13]

Financial Performance - Q2 2025 - Net sales increased to $730.9 million, an 8% increase compared to $676.5 million in Q2 2024 [33] - Gross profit reached $239.7 million, a 3.8% increase from $231.0 million in Q2 2024, but gross profit margin decreased by 130 bps to 32.8% [33] - Net income decreased by 17.7% to $37.3 million, compared to $45.3 million in Q2 2024, with net income margin declining by 160 bps to 5.1% [33] - Adjusted EBITDA increased slightly by 0.3% to $105.4 million, compared to $105.1 million in Q2 2024, but adjusted EBITDA margin decreased by 110 bps to 14.4% [33] Full Year 2025 Outlook - The company anticipates a low single-digit percentage decline in net sales for the full year 2025 [35] - Adjusted EBITDA is projected to be between $315 million and $365 million [35] - Adjusted EBITDA margin is expected to be approximately 12.0%-13.5% [35] - Adjusted diluted EPS is forecasted to be between $1.03 and $1.32 [35] Long-Term Financial Targets - The company aims for a 4-6% CAGR in net sales [40] - The company targets an adjusted EBITDA margin of approximately 16%-18% [40]

Second Quarter 2025 August 6, 2025 EARNINGS CONFERENCE CALL © 2024 Forward-Looking Statements & Non-GAAP Disclaimer Forward-Looking Statements This presentation includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning the Company's plans, goals, objectives, outlook, expectations, and intentions, including statements that are ...

These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the Company's forward-looking statements. These risks and uncertainties include, but are not limited to: consumer reaction to public health and food safety issues; increases in labor costs and fluctuations in the availability of and our ability to attract, train and retain employees; increases ...

Financial Performance - The company's total revenues increased by 9.7% year-over-year, reaching $686 million in Q2 2025, compared to $625 million in Q2 2024 [11] - Adjusted operating profit (AOP) grew by 27.8% year-over-year to approximately $134 million [8, 11] - AOP margin increased by approximately 280 basis points year-over-year to 19.5% [8, 42] - Adjusted diluted earnings per share increased to $0.58 in Q2 2025, up from $0.45 in Q2 2024 [11] - Adjusted operating costs (AOC) grew by 6.1% year-over-year [8] Subscriber Growth - The company added approximately 230,000 net digital-only subscribers in Q2 2025, bringing the total subscriber count to 11.88 million [8, 13] - Bundle and multiproduct subscribers now constitute 51% of the company's total subscriber base, an increase from 49% in Q1 2025 [8] - Total digital-only average revenue per user (ARPU) increased by 3.2% year-over-year to $9.64 [8] Revenue Streams - Digital-only subscription revenues increased by 15.1% year-over-year [8, 26] - Digital advertising revenues increased by 18.7% year-over-year [8, 33] - Affiliate, licensing, and other revenues increased by 5.8% year-over-year [8, 34] Free Cash Flow - The company generated strong free cash flow, with $455 million for the last twelve months ended June 30, 2025 [44]

Financial Performance - Q2 2025 revenue increased to $710.3 million, a 7.2% increase compared to $662.4 million in Q2 2024 [13] - Adjusted EBITDA for Q2 2025 was $54.9 million, a 0.5% decrease compared to $55.2 million in Q2 2024 [13] - Net loss for Q2 2025 was $(374.9) million, including a non-cash goodwill impairment charge of $309.1 million [13] - Adjusted net income for Q2 2025 was $17.6 million, compared to a loss of $(2.3) million in Q2 2024 [13] - The company is raising 2025 revenue guidance to $2.6 billion - $2.7 billion and reaffirming Adjusted EBITDA guidance of $170 million - $200 million [7, 20] Cash Flow and Liquidity - Free cash flow for QTD Q2 2025 was $14.3 million [16] - Gross debt as of June 30, 2025, was $1.192 billion [16] - Net debt as of June 30, 2025, was $1.1108 billion [16] - Net leverage was 5.4x based on a TTM Adjusted EBITDA of $205.4 million [16, 18] Other Key Metrics - Q2 Book-to-Bill was 0.79x, impacted by the CEO transition period [7] - Trailing 12 months Book-to-Bill was 1.10x [7]

Financial Performance - Net sales reached $1615 million in Q2 2025, a year-over-year increase of $61 million [7] - Adjusted EBITDA was $253 million in Q2 2025, up $46 million compared to Q2 2024 [7] - The company reported a net loss of $381 million in Q2 2025, compared to a net income of $60 million in Q2 2024 [7] - Adjusted EPS was $058 in Q2 2025, compared to $038 in Q2 2024 [7] - Free cash flow was $50 million in Q2 2025, a significant increase of $743 million compared to Q2 2024's negative $693 million [7] Segment Performance - TSS (Thermal & Specialized Solutions) net sales increased to $597 million in Q2 2025 [15] - TT (Titanium Technologies) net sales decreased to $657 million in Q2 2025 [15] - APM (Advanced Performance Materials) net sales slightly increased to $346 million in Q2 2025 [15] Strategic Initiatives and Outlook - Opteon Refrigerants in TSS achieved 65% year-over-year net sales growth [6] - The company announced a settlement with the State of New Jersey to resolve environmental claims, with Chemours' discounted share of settlement payments being approximately $250 million [6, 27] - Q3 2025 net sales are expected to decline 4-6% sequentially, with adjusted EBITDA between $175-$195 million [40, 41] - Full year 2025 adjusted EBITDA is projected to be between $775 million and $825 million, with net sales between $59 billion and $60 billion [44]